Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical trial to evaluate the safety and efficacy of Botulax injection for improvement of gastrocnemius hypertrophy
KCT0008039Phase 4Active, not recruiting
- Sponsor
- Hugel
- Start
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of botulinum toxin type A in gastrocnemius muscle hypertrophy (GMH), sponsored by Hugel. Started Apr 2022; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
gastrocnemius muscle hypertrophy (GMH)
Beyond the preview
Go deeper on KCT0008039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008039.